SELECT trial
Landmark trial showing semaglutide cut cardiovascular events in obesity without diabetes.
The SELECT cardiovascular outcomes trial showed semaglutide reduced major adverse cardiovascular events by ~20% in adults with obesity and established cardiovascular disease but without diabetes, supporting Wegovy's 2024 cardiovascular indication.